International cardiac angiosarcoma patient registry

Cardiac Angiosarcoma International Registry

This registry collects medical histories, tumor details, treatments, and outcomes from people with cardiac angiosarcoma to see which factors and therapies lead to better results.

Quick facts

• Study type: Observational
• Enrollment: 500 (estimated)
• Sex: All
• Sponsor: Immune Oncology Research Institute (Academic / other)
• Drugs / interventions: chemotherapy, immunotherapy, radiation
• Locations: 1 site (Yerevan)
• Trial ID: NCT06715579 on ClinicalTrials.gov

What this trial studies

This international registry will gather standardized clinical data from patients with histologically confirmed primary cardiac angiosarcoma diagnosed between 2015 and 2035. Participating centers will submit demographics, tumor characteristics, treatment regimens (surgery, chemotherapy, immunotherapy, radiation), and follow-up outcomes into a centralized database. Investigators will analyze pooled data to identify genetic, environmental, and treatment-related factors linked to survival and complications. The assembled dataset will be used to develop evidence-based recommendations and to support future clinical trials for this rare, aggressive heart cancer.

Who should consider this trial

Good fit: Ideal candidates are people with histologically confirmed primary cardiac angiosarcoma (including hemangiosarcoma and epithelioid variants) diagnosed between January 2015 and January 2035 who can provide available clinical data and, for prospective entries, informed consent.

Not a fit: Patients without a confirmed cardiac angiosarcoma diagnosis, those lacking sufficient clinical data, or those unwilling to consent are unlikely to benefit from this registry.

Why it matters

Potential benefit: If successful, the registry could identify treatments and risk factors that improve diagnosis, management, and survival for people with cardiac angiosarcoma.

How similar studies have performed: Registries and multicenter databases for rare sarcomas have improved understanding of disease patterns and treatment outcomes, but cardiac angiosarcoma-specific data remain limited and this effort is relatively novel.

Eligibility criteria

Inclusion Criteria:

* Histological Confirmation: A confirmed diagnosis of cardiac angiosarcoma through histopathological examination, including subtypes such as hemangiosarcoma and epithelioid hemangiosarcoma.
* Diagnosis Timing: Eligible patients must have been diagnosed between January 2015 and January 2035.
* Geographical Representation: Participants should be from diverse geographical locations to ensure a comprehensive understanding of the disease across different populations.
* Treatment Status: Patients who have received any treatment (surgery, chemotherapy, immunotherapy or radiation) for cardiac angiosarcoma may be included to evaluate treatment outcomes.
* Informed Consent: For prospective patients, informed consent must be obtained before they are included in the registry.
* Clinical Data Availability: Relevant clinical data, including demographics, tumor characteristics (size, location), treatment regimens, and outcomes, must be available for analysis.
* Follow-Up Willingness: Participants should be willing to undergo follow-up assessments as part of the registry's data collection efforts.

Exclusion Criteria:

* Patients who decline to provide informed consent.
* Cases where cardiac involvement is secondary to another primary malignancy

Where this trial is running

Yerevan

• Yeolyan Hematology and Oncology Center — Yerevan, Armenia (Recruiting)

Study contacts

• Principal investigator: Shushan Hovsepyan, MD — Immune Oncology Research Institute, Yerevan, Armenia
• Study coordinator: Aharon Tsaturyan, MD

Conditions Cardiac Angiosarcoma; Angiosarcoma; Hemangiosarcoma; Epithelioid Hemangiosarcoma; Primary Cardiac Sarcoma